Education
About Us
Working with TipRanks
Follow Us
Niagen Bioscience (NAGE)
NASDAQ:NAGE
NAGE Stock Chart & Stats
$6.51
--
Market closed
$6.51
--
Day’s Range― - ―
52-Week Range$5.16 - $14.69
Previous CloseN/A
VolumeN/A
Average Volume (3M)910.09K
Market Cap
$514.75M
Enterprise Value$746.92M
Total Cash (Recent Filing)$64.14M
Total Debt (Recent Filing)$3.06M
Price to Earnings (P/E)26.7
Beta0.85
Next Earnings
Mar 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding79,806,140
10 Day Avg. Volume647,243
30 Day Avg. Volume910,092
Financial Highlights & Ratios
PEG Ratio-0.22
Price to Book (P/B)9.84
Price to Sales (P/S)4.55
P/FCF Ratio37.97
Enterprise Value/Market Cap1.45
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit9.37
Enterprise Value/Ebitda35.33
Forecast
1Y Price Target
$16.33Price Target Upside150.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.18
Revenue Forecast (FY)$127.29M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNiagen Bioscience delivered encouraging financial results, reporting top-line revenue totaling $34M vs. forecast of only $31.5M.
Market GrowthThe addition of Tru Niagen Beauty helps expand Niagen's total addressable market and allows the company to participate in the fast-growing 'internal beauty' category in the US.
Product ExpansionNiagen announced the launch of Tru Niagen Beauty in the US, building on the Tru Niagen franchise and focusing on internal beauty with clinically-studied ingredients for skin, nail, and hair health.
Bears Say
Clinical Data ChallengesA study could not statistically prove improved outcomes after 5 weeks of using Niagen supplements for managing long COVID symptoms, indicating inconclusive results.
Market And Operational RisksRisks include, but are not limited to: slower-than-projected U.S. sales growth, unfavorable clinical data, adverse legal decisions, inability to achieve traction in ex-U.S. markets, and disruptions due to geopolitical risk factors.
Regulatory And Competition RisksThe FDA decision that NMN can be used in supplements could lead to more NMN products and increased competition for Niagen Bioscience.
Niagen Bioscience News
NAGE FAQ
What was Niagen Bioscience’s price range in the past 12 months?
Niagen Bioscience lowest stock price was $5.16 and its highest was $14.69 in the past 12 months.
What is Niagen Bioscience’s market cap?
Niagen Bioscience’s market cap is $514.75M.
When is Niagen Bioscience’s upcoming earnings report date?
Niagen Bioscience’s upcoming earnings report date is Mar 11, 2026 which is in 90 days.
How were Niagen Bioscience’s earnings last quarter?
Niagen Bioscience released its earnings results on Nov 04, 2025. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.018 by $0.032.
Is Niagen Bioscience overvalued?
According to Wall Street analysts Niagen Bioscience’s price is currently Undervalued.
Does Niagen Bioscience pay dividends?
Niagen Bioscience does not currently pay dividends.
What is Niagen Bioscience’s EPS estimate?
Niagen Bioscience’s EPS estimate is 0.02.
How many shares outstanding does Niagen Bioscience have?
Niagen Bioscience has 79,806,140 shares outstanding.
What happened to Niagen Bioscience’s price movement after its last earnings report?
Niagen Bioscience reported an EPS of $0.05 in its last earnings report, beating expectations of $0.018. Following the earnings report the stock price went down -1.007%.
Which hedge fund is a major shareholder of Niagen Bioscience?
Currently, no hedge funds are holding shares in NAGE
Niagen Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (150.84% Upside)
$16.33 (150.84% Upside)
Blogger Sentiment
Bullish
NAGE Sentiment 66%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 101.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $45.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.42%
12-Months-Change
Fundamentals
Return on Equity
38.90%
Trailing 12-Months
Asset Growth
73.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Niagen Bioscience
Niagen Bioscience (NAGE) is a biotechnology company focused on the development and commercialization of innovative health solutions that harness the power of nicotinamide riboside (NR), a precursor to NAD+, a critical coenzyme involved in cellular metabolism and energy production. Operating primarily in the health and wellness sector, the company offers a range of products aimed at enhancing cellular health and longevity, targeting both consumers and businesses in the dietary supplement market.
NAGE Company Deck
NAGE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong performance with record revenue growth and strategic expansions. However, challenges remain in regulatory environments and pricing strategies in certain markets.View all NAGE earnings summariesNAGE Stock 12 Month Forecast
Average Price Target
$16.33
▲(150.84% Upside)
Technical Analysis
Iovance Biotherapeutics
―
Kura Oncology
―
Vir Biotechnology
―
Fortrea Holdings Inc.
―
Septerna, Inc.
―
Ownership Overview
4.99% Insiders
9.25% Mutual Funds
6.97% Other Institutional Investors
70.65% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---